NUI Galway research will advance the treatment of Crohn’s disease

A team of researchers from NUI Galway have discovered a radically new approach to the treatment of Crohn’s disease and ulcerative colitis.

The study identified a breakthrough therapeutic strategy to restore the gut lining of patients with the disease and other inflammatory bowel diseases.

The treatment could also help prevent further inflammation, which is how the disease progresses and gets worse over time.

NUI Galway CÚRAM researchers have designed a hyaluronan (HA) enema, which has shown significant potential in protecting against damage to the intestinal mucosa by decreasing inflammation and helping to maintain mucosal health intestinal.

Crohn’s disease and ulcerative colitis, or IBD, are characterized by chronic inflammation of the gastrointestinal tract and affect more than 3.2 million people in Europe.

“The team is confident that the developed system can be administered as an HA enema to act as a protective system against the damaged colonic barrier, thereby reducing intestinal inflammation in the treatment of inflammatory bowel disease,” said Professor Abhay Pandit, scientific director of CÚRAM.

“This will result in a reduction of inflammation and protection of the intestinal mucosa.”

The research represents a significant leap forward from standard therapeutic interventions for colitis, which have primarily focused on maintaining levels of remission and do not address the root cause of the disease, specifically damage to the intestinal lining and to bowel function.

Dr. Niranjan Kotla conducted the principal research for the study at CÚRAM in collaboration with Dr. Venkatakrishna R Jala, Department of Microbiology and Immunology, James Graham Brown Cancer Center, University of Louisville, USA.

Dr. Yury Rochev, co-editor of the publication, added: “This research demonstrates the efficacy of a unique therapeutic strategy capable of inducing a positive effect on damaged colonic tissue. The reduction in inflammation will be of great benefit to patients and highlights the potential use of this treatment.

Comments are closed.